Cardiac Effects of Renin-Angiotensin System Inhibitors in Nonproteinuric CKD

医学 危险系数 内科学 比例危险模型 肾脏疾病 心肌梗塞 心力衰竭 冲程(发动机) 蛋白尿 队列 心脏病学 肾功能 置信区间 机械工程 工程类
作者
Richard S. Shulman,Wei Yang,Debbie L. Cohen,Peter P. Reese,Jordana B. Cohen,Lawrence J. Appel,Jing Chen,Harold I. Feldman,Alan S. Go,James P. Lash,Robert G. Nelson,Mahboob Rahman,Panduranga S. Rao,Vallabh O. Shah,Mark Unruh
出处
期刊:Hypertension [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1161/hypertensionaha.124.23184
摘要

BACKGROUND: In contrast to proteinuric chronic kidney disease (CKD), the relative cardioprotective benefits of antihypertensive medications in nonproteinuric CKD are unknown. We examined long-term cardiovascular outcomes and mortality in patients with nonproteinuric CKD treated with renin-angiotensin system inhibitors (RASIs) versus other antihypertensive medications. METHODS: Among participants of the CRIC study (Chronic Renal Insufficiency Cohort) without proteinuria, we used intention-to-treat analyses with inverse probability of treatment weighting and Cox proportional hazards modeling to determine the association of RASIs versus other antihypertensive medications with a composite cardiovascular outcome (myocardial infarction, stroke, heart failure hospitalization, and death) and mortality. Secondary analyses included per-protocol analyses accounting for continuous adherence and time-updated analyses accounting for the proportion of time using RASIs during follow-up. RESULTS: A total of 2806 participants met the inclusion criteria. In the intention-to-treat analyses, RASIs versus other antihypertensive medications were not associated with an appreciable difference in cardiovascular events (adjusted hazard ratio [aHR], 0.94 [95% CI, 0.80–1.11]) or mortality (aHR, 1.06 [95% CI, 0.88–1.28]). In the per-protocol analyses, RASIs were associated with a lower risk of adverse cardiovascular events (aHR, 0.78 [95% CI, 0.63–0.97]) and mortality (aHR, 0.64 [95% CI, 0.48–0.85]). Similarly, in the time-updated analyses, a higher proportion of RASI use over time was associated with a lower mortality risk (aHR, 0.33 [95% CI, 0.14–0.86]). CONCLUSIONS: Among individuals with nonproteinuric CKD, after accounting for time-updated use, RASIs are associated with fewer cardiovascular events and a lower mortality risk compared with other antihypertensive medications. Patients with nonproteinuric CKD may benefit from prioritizing RASIs for hypertension management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
沙比完成签到,获得积分10
1秒前
一一完成签到,获得积分10
1秒前
MicroCytoYL完成签到,获得积分10
2秒前
2秒前
一只特立独行的朱完成签到,获得积分10
2秒前
步行街车神ahua完成签到,获得积分10
2秒前
2秒前
keran完成签到,获得积分20
2秒前
1111发布了新的文献求助10
2秒前
动如脱兔发布了新的文献求助10
3秒前
starry完成签到,获得积分10
3秒前
4秒前
Grayball应助愉快的冰珍采纳,获得10
4秒前
4秒前
5秒前
Pangsj发布了新的文献求助10
5秒前
5秒前
5秒前
yzy完成签到,获得积分20
6秒前
7秒前
7秒前
Hang发布了新的文献求助10
7秒前
最初发布了新的文献求助10
8秒前
Lesile完成签到,获得积分10
8秒前
竹筏过海应助公西翠萱采纳,获得30
8秒前
8秒前
海子完成签到,获得积分10
9秒前
沉敛一生发布了新的文献求助10
9秒前
柏忆南完成签到 ,获得积分10
9秒前
li发布了新的文献求助10
9秒前
dldddz发布了新的文献求助10
9秒前
jimmy完成签到,获得积分10
9秒前
田様应助侦察兵采纳,获得10
9秒前
鑫渊完成签到,获得积分10
9秒前
天冷了hhhdh完成签到,获得积分10
10秒前
ting完成签到,获得积分10
10秒前
微笑完成签到,获得积分10
10秒前
可爱的函函应助西宁阿采纳,获得30
11秒前
蓝莓松饼发布了新的文献求助10
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527304
求助须知:如何正确求助?哪些是违规求助? 3107454
关于积分的说明 9285518
捐赠科研通 2805269
什么是DOI,文献DOI怎么找? 1539827
邀请新用户注册赠送积分活动 716708
科研通“疑难数据库(出版商)”最低求助积分说明 709672